Dr. Sunil Kumar Singh has been a post-doctoral researcher at the University of Illinois, Chicago, USA, since October 2016. He completed his master’s degree at Visva Bharati, India, and obtained his doctorate from the Central Drug Research Institute, India. He has extensive experience in the field of life science, particularly in cancer research. His current research focuses on the MLK3-mediated MAP kinase signaling cascade and its implications for cancer. Additionally, he has established the correlation between MAP4K4 and KRAS in pancreatic cancers. KRAS belongs to a class of genes known as oncogenes. Dr. Singh has experience working with molecular biology techniques and has conducted in vitro and in vivo assays related to cancer research and drug development.